Shattuck Labs : May 02, 2023 Shattuck Labs Corporate Presentation

Corporate Overview

NASDAQ: STTK

May 2, 2024

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on our estimates and assumptions. All statements, other than statements of historical facts included in this presentation, are forward-looking statements, including statements concerning our plans, objectives, goals, strategies, future events, or intentions relating to products and markets; the safety, efficacy and clinical benefits of our product candidates, alone or in combination with other agents; the anticipated timing and design of our planned and ongoing preclinical studies and clinical trials, including initiation of additional cohorts, enrollment, the anticipated timing for data, the association of preclinical data with potential clinical benefit, and the timing of anticipated milestones; plans and objectives of management for future operations and future results of anticipated product development efforts, including with respect to preclinical product candidates; potential benefits of our strategic partnerships; potential addressable market size; our anticipated cash runway; and our liquidity and capital resources and business trends. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan," or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this presentation, in addition to those risks and uncertainties, such as the uncertainties inherent in the clinical drug development process, the regulatory approval process, the timing of our regulatory filings, the potential for substantial delays, the risk that earlier study results may not be predictive of future study results, manufacturing risks, and competition from other therapies or products, described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K (File No. 001-39593) for the fiscal year ended December 31, 2023 and elsewhere in such filing and in our other periodic reports and subsequent disclosure documents filed with the U.S. Securities and Exchange Commission.

We cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. Forward-looking statements are not historical facts, and reflect our current views with respect to future events. Given the significant uncertainties, you should evaluate all forward-looking statements made in this presentation in the context of these risks and uncertainties and not place undue reliance on these forward-looking statements as predictions of future events. All forward-looking statements in this presentation apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this presentation. We have no intention to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by law.

We obtained the data used throughout this presentation from our own internal estimates and research, as well as from research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released and our own internal research and experience, and are based on assumptions made by us based on such data and our knowledge, which we believe to be reasonable. In addition, while we believe the data included in this presentation is reliable and based on reasonable assumptions, we have not independently verified any third-party information, and all such data involve risks and uncertainties and are subject to change based on various factors.

This presentation concerns a discussion of investigational drugs that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.

2

Shattuck Labs

Focused on Improving the Lives of Patients

OUR PURPOSE

Pioneering Novel Therapeutics for Cancer and Autoimmune Diseases

OUR VALUES

Bold, Respectful, Honest, Balanced, Grateful

OUR MISSION

Work with a sense of urgency, focused on scientific excellence and thoughtful stewardship of resources, to translate innovative ideas into medicines that improve the lives of patients with serious diseases

OUR VISION

Build incredible medicines off the beaten path by challenging ourselves to think differently

Shattuck Labs Overview

Shattuck Labs (NASDAQ: STTK)

Agonist Redirected Checkpoint (ARC) Platform

ARC Clinical Pipeline Against Validated Oncology Targets

Discovery Platform

Experienced Team and Strong Cash Position

Clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins, with key clinical data from multiple expansion cohorts expected in 2024

• Checkpoint inhibition + costimulatory pathway activation
• High binding affinity and avidity to targets
• Rapid concept to compound to clinic

SL-172154: CD47/SIRPα Inhibitor CD40 Agonist

Multiple Phase 1B clinical trials ongoing in PROC and AML/HR-MDS

• Strategic partnership with Ono Pharmaceutical to develop bifunctional fusion proteins for the treatment of autoimmune and inflammatory diseases
• Highly experienced management team, board of directors, and scientific advisory board
• $114.6 million in cash and cash equivalents and investments as of March 31, 2024
• Cash runway expected to fund operations into 2026

PROC = Platinum-Resistant Ovarian Cancer

4 AML = Acute Myeloid Leukemia

HR-MDS = Higher-Risk Myelodysplastic Syndromes

Shattuck's Clinical-Stage Pipeline

Targeting CD47/SIRPα and CD40 Pathways

		Domains				Stage of Development
Platform	Program	Domain 1	Domain 2	Indications	Combination	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Agents
				PROC	Liposomal
				Doxorubicin
				PROC	Mirvetuximab
				Soravtansine
ARC	SL-172154	SIRPα	CD40L
TP53m AML	Azacitidine

HR-MDSAzacitidine

TP53wt AML1	Azacitidine
+ Venetoclax

➔ Developing potential first-in-class CD47 inhibitor in PROC and best-in-class in AML/HR-MDS

1. Potential future cohort, not currently enrolling

5 TP53m = TP53 mutant TP53wt = TP53 wild type

Agonist Redirected Checkpoint (ARC®) Platform

A New Class of Biologic Medicines

6

ARC Platform Technology

Designed to Simultaneously Block Immune Checkpoints and Activate TNF Receptors

6 Checkpoint Binding Domains

Components

Type 1 Extracellular Domains

Fc Domains

Optimized for Target

Type 2 Extracellular Domains

6 TNF Receptor Binding Domains

(Two Sets of TNF Trimers)

Key Advantages

Plug & Play

Modular Technology

12 Binding Domains

High Avidity + Affinity

Hexavalent Binding

2 Distinct Targets

• Tumor necrosis factor, or TNF, receptor superfamily pathways are central to immune cell
  function, but effective activation requires trimerization

7

Current Antibody Therapy Approaches Have Limitations

Bivalent Antibodies Cannot Efficiently Activate Trimeric Receptors

A.

B.

C.

		ARC COMPOUND
		ANTIBODY
		(BIVALENT BINDING)
TNF RECEPTORS	TNF RECEPTOR	2 SETS OF TRIMERS
(TRIMER)	(DIMER)

1. CELL

TNF receptors require	Bivalent antibodies cannot bring	ARCs contain two preformed TNF
trimerization for effective activation,	together TNF receptors to form a	ligand trimers, which match the
and hexamers signal even more	trimer due to a	requisite structure to efficiently
effectively than trimers1	structural mismatch	activate TNF receptor signaling

8 1. Vanamee E et al. Science Signaling Jan 2018

Highly Experienced Management and Board

Established Track Record of Drug Discovery and Development

Management Team

Taylor Schreiber, MD, PhD	Lini Pandite, MD, MBA	Casi DeYoung, MBA	Andrew R. Neill, MBA	Abhinav Shukla, PhD	George Fromm, PhD	Suresh de Silva, PhD	Stephen Stout, PhD
Chief Executive Officer	Chief Medical Officer	Chief Business Officer	Chief Financial Officer	Chief Technical Officer	Co-Chief Scientific Officer	Co-Chief Scientific Officer	General Counsel,

Corporate Secretary and

Chief Ethics and

Compliance Officer

Board of Directors

Helen M. Boudreau	Tyler Brous	Carrie Brownstein, MD	Neil Gibson, PhD	George Golumbeski, PhD	Michael Lee	Taylor Schreiber MD, PhD
CFO of Proteostasis,	Portfolio Manager,	CMO of Zentalis; VP of	Chief Scientific Officer,	Chairman of the Board;	Redmile Group	Chief Executive Officer,
FORMA, Novartis US	Lennox Capital Partners,	Global Clinical R&D,	COI Pharma; Chief	EVP of Business		Shattuck
	LP	Myeloid Diseases,	Scientific Officer, Pfizer	Development, Celgene
		Celgen	Oncology

9	Note: italicized text denotes prior affiliation

Focused on Developing Groundbreaking Therapeutics

Addressing Significant Unmet Medical Need

Innovative

Science

Scientific expertise

drives identification of optimized combination of checkpoint inhibition and TNF agonism

Multiple 2024

Catalysts

Phase 1 data readouts

in solid tumors and

hematologic

malignancy programs

(PROC, AML/HR-MDS)

Long-Term Growth

Potential

Potential first-in-class CD47 inhibitor, ARC platform generating

diverse potential

clinical candidates

Financial

Strength

Financial position expected to fund operations into 2026

and multiple inflection

points

10